​​The first domestic imitation of Lacosamide Oral Solution is approved.

On April 15, 2022, the National Drug Administration approves the production and listing of Lacosamide Oral Solution (National Drug Approval Number H20223222), which lets Shandong Loncom Pharmaceutical Co.,Ltd. be the first successful imitation enterprise on this product in China.

Lacosamide Oral Solution is developed by Shandong Loncom Pharmaceutical Co.,Ltd. and is suitable for the combined treatment of partial seizures in epilepsy patients aged 4 years and above. Epilepsy is a common paroxysmal nervous system disease, which is listed as one of the five intractable diseases of the nervous system by the World Health Organization. It is also the second largest persistent disease among nervous system diseases, only next to cerebrovascular diseases. The incidence rate of children is far higher than that of adults. Oral solution has fast absorption, rapid efficacy, accurate dosage distribution, and convenient administration. This variety has been approved, which has improved the compliance of pediatric patients with medication and solved the problem of swallowing difficulties or the need for nasal feeding or gastrostomy. Lacosamide Oral Solution has obvious clinical advantages and is an important variety of antiepileptic drugs, which brings good news to epilepsy patients and their families.